文献速递骨质疏松与代谢性骨病

比较生物类似药RGB-14-P与地舒单抗在绝经后骨质疏松女性中疗效与安全性的3期研究:转换(切换)阶段结果

Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase.
PubMed 文献 · Osteoporos Int · 2026-03-24

这项3期研究纳入188例绝经后骨质疏松女性,在52周时重新随机分组继续RGB-14-P、继续参照地舒单抗(RD)或从RD转换为RGB-14-P,随访至78周。结果显示三组腰椎、髋部和股骨颈骨密度增益从52周至78周进一步改善,新发脆性骨折发生率相当,药效学标志物变化维持,转换未诱导可辨别的免疫反应,安全性无临床有意义组间差异。

要点

  • 从参照地舒单抗转换为RGB-14-P后疗效持续且进一步提升。
  • 转换未诱导可辨别的免疫反应,安全性无临床有意义差异。
  • RGB-14-P与参照地舒单抗在52周内显示等效疗效。

核心结论

  • RGB-14-P与参照地舒单抗在绝经后骨质疏松女性中显示等效疗效和相似的安全性、药效学及免疫原性。
  • 从参照地舒单抗转换为RGB-14-P对疗效、药效学、免疫原性或安全性无可辨别影响。

研究设计与样本

  • 随机、盲法、对照3期研究,188例绝经后骨质疏松女性先前接受两剂60 mg RGB-14-P或参照地舒单抗(第1天和第26周)。
  • 第52周按1:1:1重新随机分为继续RGB-14-P(n=63)、继续参照地舒单抗(n=63)或从参照地舒单抗转换为RGB-14-P(n=62),随访至第78周。

主要发现

  • 三组腰椎、髋部和股骨颈骨密度增益从治疗前52周至第78周进一步改善,包括从参照地舒单抗转换为RGB-14-P的患者。
  • 新发脆性骨折发生率相当。
  • 血清药效学标志物(血清I型胶原C端肽和I型前胶原N端前肽)从基线的变化维持。
  • 转换未诱导可辨别的免疫反应,安全性无临床有意义组间差异。

临床怎么用

  • RGB-14-P可考虑用于长期治疗以及地舒单抗治疗的延续。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoporosis is a chronic condition requiring long-term management of fracture risk. Biosimilars provide the possibility of continuous use of well-established compounds. Proposed denosumab biosimilar RGB-14-P demonstrated equivalent efficacy and similar pharmacodynamics, immunogenicity, and safety to the reference denosumab. Transitioning from reference denosumab to RGB-14-P was associated with continued effectiveness and safety. PURPOSE: To establish the therapeutic equivalence of RGB-14-P and reference denosumab (RD) in postmenopausal women with osteoporosis through demonstrating equivalent efficacy and similar safety, pharmacodynamics (PD), and immunogenicity when transitioning from RD to RGB-14-P. METHODS: Patients (n = 188) who had received two 60-mg doses of RGB-14-P or RD (day 1 and week 26) in a randomised, blinded, controlled phase 3 study were re-randomised 1:1:1 at week 52 to continue RGB-14-P (n = 63) or RD (n = 63) or transition from RD to RGB-14-P (n = 62) and followed to week 78. RESULTS: Gains in lumbar spine, hip, and femoral neck bone mineral density (BMD) observed in the first 52 weeks of treatment were further improved up to week 78 in all three groups, including patients who transitioned from RD to RGB-14-P. Incidences of new fragility fractures were comparable. Changes from baseline in serum PD markers (serum C-telopeptide of type I collagen and procollagen type I N-terminal propeptide) were maintained. The transition did not induce a discernible immunological reaction, and there were no clinically meaningful between-group differences in safety. CONCLUSION: Treatment responses to RGB-14-P or RD seen during the first 52 weeks of treatment further improved to week 78; transitioning from RD to RGB-14-P had no discernible impact on efficacy, PD, immunogenicity, or safety. The totality of the evidence on the proposed biosimilar RGB-14-P available to date demonstrated structural and functional similarity as well as PK, PD, and therapeutic equivalence to reference denosumab, which suggests that RGB-14-P can be considered for long-term treatment, as well as a continuation of denosumab treatment.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ferrari S, Seefried L, Páll D, et al. Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase. Osteoporos Int. 2026. PMID: 41876722. doi:10.1007/s00198-026-07964-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。